Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics (VERA – Research Report) and keeping the price target at $70.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight the promising potential of Vera Therapeutics’ atacicept in treating IgA nephropathy (IgAN). The recent positive data from the Phase III ORIGIN 3 study showed a significant reduction in proteinuria, which aligns with the optimistic expectations for the treatment’s efficacy. The safety profile of atacicept is also comparable to placebo, which supports its favorable risk-benefit assessment.
Furthermore, the company’s plan to meet with the FDA and submit a Biologics License Application (BLA) for accelerated approval by Q4 2025 indicates a clear regulatory pathway. The potential for atacicept to be utilized in a first-line setting, alongside existing treatments, underscores its commercial viability in a market estimated to be worth around $10 billion. These factors, combined with the early commercial launch prospects supported by previous eGFR stabilization results, contribute to the Buy rating.
According to TipRanks, Katkhuda is a 4-star analyst with an average return of 13.0% and a 41.04% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Dianthus Therapeutics, and Tourmaline Bio.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $85.00 price target.